Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Jul 6, 2018
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Sale
Common Stock
2018-07-06$28.35/sh−393$11,142→ 4,750 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.